Chronic Kidney Disease Drugs Market – Global Forecast to 2025
  • ID: 1334
  • March 26, 2019
  • 85 pages
  • Infoholic Research

Global Chronic Kidney Disease Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[85 pages report] This market research report includes a detailed segmentation of the global chronic kidney disease drugs market by drug class (antihypertensives, antihyperlipidemics, erythropoiesis-stimulating agents (ESAs), diuretics, and others), by end-users (hospitals and specialty clinics), by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Chronic Kidney Disease Drugs Market
Infoholic’s market research report predicts that the “Global Chronic Kidney Disease Drugs Market” will grow at a CAGR of 4.1% during the forecast period. The market has witnessed flat growth in the past few years and is sustaining only due to the steady rise in the incidence of renal disorders leading to chronic kidney disease, increasing incidences of cardiovascular and metabolism-related disorders, and growing geriatric population globally.

The growing market trend continues and is one of the increasingly accepted markets in many countries worldwide. Chronic kidney disease drugs manufacturers are focusing on obtaining funds and collaborating with universities to enlarge their R&D capabilities. A majority of the revenue is generated from the leading players in the market with dominant sales from AbbVie, Amgen, GlaxoSmithKline, Roche, and AstraZeneca.
According to Infoholic Research analysis, North America accounted for the largest share of the global chronic kidney disease drugs market in 2018. The US dominates the market owing to the presence of a majority of the chronic kidney disease drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the large kidney disease patient population and increasing awareness about the disease.
By Drug Class:
• Antihypertensives
• Antihyperlipidemics
• Erythropoiesis-stimulating agents (ESAs)
• Diuretics
• Others
The antihypertensives segment occupied the largest share in 2018. Currently, KBP Biosciences and Medpace, Inc. are conducting Phase 2 randomized clinical trial on KBP-5074 for patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
By End-users:
• Hospitals
• Specialty Clinics
In 2018, hospitals accounted for the maximum share, followed by specialty clinics, due to the availability of technologically-advanced diagnostic equipment for the early diagnosis of the condition.
By Regions:
• North America
• Europe
• APAC
• RoW
North America is dominant in the global chronic kidney disease drugs market, followed by Asia Pacific and Europe. The significant share of the North America market comes from the US due to the availability of good reimbursement policies.
Chronic Kidney Disease Drugs Market Research Competitive Analysis – The market is growing at a flat rate, with a single-digit CAGR during the forecast period. Various initiatives are taken by government establishments and market players to increase awareness among individuals. Campaigns are conducted globally to encourage people in adopting healthy lifestyles. Many countries are focusing on national programs to create disease awareness, prevention, and treatment options; for example, country-level national dialysis program, kidney disease education portals, launch of kidney-related disorder treatment funding initiatives, etc. Exhaustive pipeline for chronic kidney disease drugs is promising and is much required for future market growth. For example, ROXADUSTAT (HIF-PHI) by FibroGen is currently being studied in Phase-III clinical trials in the US, Europe, China, and Japan. Dapagliflozin by AstraZeneca is currently in phase III to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD).
Key Vendors:
• AbbVie Inc.
• Amgen Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
Key Competitive Facts
• Increasing CKD incidence, aging population, promising repayment or reimbursement plans in few nations, and enormous R&D activities for the CKD drug development are the major factors driving the market growth.
• Cell therapy produces better results in the earlier stages of kidney disease and has been shown to eliminate or reduce the need for regular dialysis.
• Research is being conducted to study the potential of miRNA as effective biomarkers and therapeutic targets for CKD treatments.
Benefits – The report provides complete details about the sub-segments of the chronic kidney diseases drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of chronic kidney diseases drugs industry.
• Factors influencing the growth of the chronic kidney disease drugs market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the chronic kidney diseases drugs market in both developed and developing regions.
• Key insights related to major segments of the chronic kidney diseases drugs market.
• Latest market trend analysis impacting the buying behavior of the consumers.
Key Stakeholders

Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Total Addressable Market 9
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Market Definition – Infoholic Research 14
3.2 Segmented Addressable Market (SAM) 14
3.3 Industry Trends 15
3.4 Related Markets 16
3.4.1 Active pharmaceutical ingredients (APIs) 16
3.4.2 Over-the-counter drugs (OTC) 16
3.4.3 Human Insulin 17
4 Market Outlook 19
4.1 Market Segmentation 19
4.2 Porter 5 (Five) Forces 19
5 Market Characteristics 22
5.1 Market Dynamics 22
5.1.1 Drivers 23
5.1.1.1 High incidence of chronic kidney disease (CKD) 23
5.1.1.2 Rise in incidence of cardiovascular disorders and diabetes 23
5.1.1.3 Increase in global geriatric population 23
5.1.2 Restraints 24
5.1.2.1 Competition from biosimilars 24
5.1.2.2 Complex drug development process 25
5.1.3 Opportunities 25
5.1.3.1 Promising Drug Pipeline Chronic Kidney Disease 25
5.1.3.2 Market expansion opportunities in emerging nations 27
5.1.3.3 Novel therapeutic approaches such as cell therapy 27
5.1.4 DRO – Impact Analysis 28
5.2 Key Stakeholders 29
6 Drug Class: Market Size and Analysis 30
6.1 Overview 30
6.2 Anti-hypertensives 31
6.1 Anti - hyperlipidemic 32
6.2 Erythropoiesis-stimulating agents (ESAs) 33
6.3 Diuretics Drugs 35
6.4 Others 36
7 End Users: Market Size and Analysis 38
7.1 Overview 38
7.2 Hospitals 38
7.3 Specialty Clinic 39
8 Regions: Market Size and Analysis 40
8.1 Overview 40
8.2 North America 42
8.2.1 Overview 42
8.3 Europe 43
8.3.1 Overview 43
8.4 Asia Pacific 45
8.4.1 Overview 45
8.5 Rest of the World 46
8.5.1 Overview 46
9 Competitive Landscape 49
10 Vendors Profile 51
10.1 AbbVie Inc. 51
10.1.1 Overview 51
10.1.2 Geographic Presence 54
10.1.3 Business Focus 54
10.1.4 SWOT Analysis 55
10.1.5 Business Strategies 55
10.2 Amgen Inc. 56
10.2.1 Overview 56
10.2.2 Geographic Presence 59
10.2.3 Business Focus 59
10.2.4 SWOT Analysis 59
10.2.5 Business Strategies 60
10.3 GlaxoSmithKline plc 60
10.3.1 Overview 60
10.3.2 Geographic Presence 63
10.3.3 Business Focus 64
10.3.4 SWOT Analysis 64
10.3.5 Business Strategies 65
10.4 F. Hoffmann-La Roche Ltd. 66
10.4.1 Overview 66
10.4.2 Business Units 67
10.4.3 Geographic Revenue 68
10.4.4 Business Focus 69
10.4.5 SWOT Analysis 69
10.4.6 Business Strategies 70
10.5 Astra Zeneca PLC 71
10.5.1 Overview 71
10.5.2 Geographic Presence 75
10.5.3 Business Focus 75
10.5.4 SWOT Analysis 76
10.5.5 Business Strategies 76
11 Companies to Watch for 77
11.1 Pfizer Inc. 77
11.1.1 Overview 77
11.2 Sanofi 78
11.2.1 Overview 78
11.3 Teva Pharmaceutical Industries Ltd. 79
11.3.1 Overview 79
11.4 Johnson & Johnson 80
11.4.1 Overview 80
11.5 Keryx Biopharmaceuticals Inc 81
11.5.1 Overview 81
11.6 FibroGen Inc. 82
11.6.1 Overview 82
Annexure 84
 Acronyms 84


Tables

TABLE 1 FDA APPROVED DRUGS FOR NEPHROLOGY 2015-2018 9
TABLE 2 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE, BY DRUG CLASS, 2018-2025 ($MILLION) 30
TABLE 3 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2018-2025 ($MILLION) 41
TABLE 4 ABBVIE INC.: OFFERINGS 51
TABLE 5 ABBVIE INC.: RECENT DEVELOPMENTS 51
TABLE 6 AMGEN INC.: OFFERINGS 56
TABLE 7 AMGEN INC.: RECENT DEVELOPMENTS 56
TABLE 8 GLAXOSMITHKLINE PLC: OFFERINGS 61
TABLE 9 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 61
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 66
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 66
TABLE 12 ASTRAZENECA PLC: OFFERINGS 71
TABLE 13 ASTRAZENECA PLC: RECENT DEVELOPMENTS 72
TABLE 14 PFIZER INC.: SNAPSHOT 77
TABLE 15 MERCK KGAA: RECENT DEVELOPMENTS 77
TABLE 16 SANOFI: SNAPSHOT 78
TABLE 17 SANOFI: RECENT DEVELOPMENTS 78
TABLE 18 TEVA PHARMACEUTICAL INDUTRIES.: OVERVIEW 79
TABLE 19 TEVA PHARMACEUTICAL INDUTRIES: RECENT DEVELOPMENTS 79
TABLE 20 EDITAS MEDICINE: OVERVIEW 81
TABLE 21 EDITAS MEDICINE.: RECENT DEVELOPMENTS 81
TABLE 22 KERYX BIOPHARMACEUTICALS, INC: SNAPSHOT 81
TABLE 23 KERYX BIOPHARMACEUTICALS, INC: RECENT DEVELOPMENTS 82
TABLE 24 FIBROGEN INC.: OVERVIEW 82
TABLE 25 FIBROGEN INC.: RECENT DEVELOPMENTS 82


Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL CHRONIC KIDNEY DISEASES DRUGS MARKET 12
CHART 2 STAGES OF CHRONIC KIDNEY DISEASE 14
CHART 3 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE, 2018-2025 ($MILLION) 15
CHART 4 CHRONIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION 19
CHART 5 PORTERS 5 FORCES ON CHRONIC KIDNEY DISEASE DRUGS MARKET 19
CHART 7 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES 22
CHART 8 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960–2060 (%) 24
CHART 9 DRO - IMPACT ANALYSIS OF CHRONIC KIDNEY DISEASES DRUGS MARKET 28
CHART 10 KEY STAKEHOLDERS OF CHRONIC KIDNEY DISEASE DRUGS MARKET 29
CHART 11 CHRONIC KIDNEY DISEASES DRUGS MARKET SEGMENT REVENUE BY DRUG CLASS, 2018 VS 2025 ($ MILLION) 30
CHART 12 ANTI-HYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS 2018-2025 ($MILLION) 32
CHART 13 ANTI-HYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS 2018-2025 ($MILLION) 33
CHART 14 ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) MARKET REVENUE, BY DRUG CLASS 2018-2025 ($MILLION) 34
CHART 15 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE, BY DRUG CLASS 2018-2025 ($MILLION) 36
CHART 16 OTHER CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE, BY DRUG CLASS 2018-2025 ($MILLION) 37
CHART 17 GLOBAL CHRONIC KIDNEY DISEASE DRUGS MARKET SEGMENT REVENUE, BY END USERS, 2018 (%) 38
CHART 18 CHRONIC KIDNEY DISEASE DRUGS MARKET BY REGIONAL SEGMENTATION, 2018 VS 2025 ($MILLION) 40
CHART 19 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE IN NORTH AMERICA, 2018-2025 ($MILLION) 43
CHART 20 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE IN EUROPE, 2018-2025 ($MILLION) 44
CHART 21 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018-2025 ($MILLION) 46
CHART 22 CHRONIC KIDNEY DISEASE DRUGS REVENUE IN REST OF THE WORLD, 2018-2025 ($MILLION) 47
CHART 23 ABBVIE INC.: OVERVIEW SNAPSHOT 52
CHART 24 ABBVIE INC.: GEOGRAPHIC PRESENCE 54
CHART 25 ABBVIE INC.: SWOT ANALYSIS 55
CHART 26 AMGEN INC.: OVERVIEW SNAPSHOT 57
CHART 27 AMGEN INC.: GEOGRAPHIC PRESENCE 59
CHART 28 AMGEN INC.: SWOT ANALYSIS 59
CHART 29 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 61
CHART 30 GLAXOSMITHKLINE PLC: BUSINESS UNITS 62
CHART 31 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE 63
CHART 32 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 64
CHART 33 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 66
CHART 34 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 67
CHART 35 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE 68
CHART 36 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 69
CHART 37 ASTRAZENECA PLC: OVERVIEW SNAPSHOT 71
CHART 38 ASTRA ZENECA PLC: BUSINESS UNITS 74
CHART 39 ASTRAZENECA PLC: GEOGRAPHIC PRESENCE 75
CHART 40 ASTRA ZENECA PLC: SWOT ANALYSIS 76

None

AbbVie Inc.
Amgen Inc.
GlaxoSmithKline plc
Hoffmann-La Roche Ltd.
AstraZeneca

Custom Research

Looking for more specific research study and analysis? Contact our Custom Research Team

Write to Custom Research Team